Kiora Pharmaceuticals (KPRX) Depreciation & Amortization (CF) (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Depreciation & Amortization (CF) came in at $10563.0 in Q1 2026, up 3221.7% YoY from $318.0 in Q1 2025, and up 0.52% on a QoQ basis from $10508.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $10563.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 3221.7% year-over-year to $10563.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35046.0 (up 139.16% YoY) and the FY2025 annual result came in at $24801.0, up 29.14% from the prior year.
- Depreciation & Amortization (CF) advanced to $10563.0 in Q1 2026, from $10508.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $22477.0 in Q2 2023 to a low of $318.0 in Q1 2025.
- A 5-year average of $8704.5 and a median of $10270.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) sank 93.47% — and 2026, when it jumped 3221.7%.
- Tracing KPRX's Depreciation & Amortization (CF) over 5 years: stood at $10285.0 in 2022, then retreated by 22.85% to $7935.0 in 2023, then dropped by 25.49% to $5912.0 in 2024, then jumped by 77.74% to $10508.0 in 2025, then rose by 0.52% to $10563.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $10563.0 (Q1 2026), $10508.0 (Q4 2025), and $10552.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | 10,741.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10,741.00 |
| Jun 30, 2026 | 10,741.00 |
| Mar 31, 2026 | 10,563.00 |
| Mar 31, 2026 | 10,563.00 |
| Dec 31, 2025 | 10,508.00 |
| Dec 31, 2025 | 10,508.00 |
| Sep 30, 2025 | 10,552.00 |
| Sep 30, 2025 | 10,552.00 |
| Jun 30, 2025 | 3,423.00 |
| Jun 30, 2025 | 3,423.00 |
| Mar 31, 2025 | 318.00 |
| Mar 31, 2025 | 318.00 |
| Dec 31, 2024 | 5,912.00 |
| Dec 31, 2024 | 5,912.00 |
| Sep 30, 2024 | 2,095.00 |
| Sep 30, 2024 | 2,095.00 |
| Jun 30, 2024 | 6,329.00 |
| Jun 30, 2024 | 6,329.00 |
| Mar 31, 2024 | 4,869.00 |
| Mar 31, 2024 | 4,869.00 |